arrow
H

Hironobu Hashimoto

National Cancer Center Hospital
H指数:30
被引数:3,476

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Central nervous system symptom burden and clinical implications for antiemetic management with olanzapine in AC chemotherapy

中枢神经系统症状负担及奥氮平在AC化疗中抗恶心管理的临床意义

2026-09-090
OAAI
Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid Tumor

早期霉酚酸酯联合疗法作为实体瘤患者免疫检查点抑制剂诱导的免疫相关肝炎的有效治疗方法

2026-03-190
OAAI
Chemotherapy-related hand–foot syndrome and hand–foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study team

化疗相关性手足综合征和手足皮肤反应:日本药师主导的肿瘤皮肤学研究小组对亚洲患者管理及可能方法的综述

2025-10-060
OA
Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team

表皮生长因子受体抑制剂相关皮肤毒性的管理及亚洲患者可能的预防和治疗方法的综述:日本药剂师主导的肿瘤皮肤学研究小组报告

2025-09-010
OAAI
A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT)

一项随机、双盲、安慰剂对照的III期研究,评估双氯芬酸乳膏对卡培他滨相关手足综合征的预防效果:J-SUPPORT2401/JORTC-SUP06(J-DIRECT)研究方案

2025-05-140
OA
Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
2023-07-241
OAAI
Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study
2022-04-2117
OAAI
Association between the Co-administration of Histamine H2 Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
2022-01-010
OAAI
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
2021-11-082
OAAI